Patrick Dorr

Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity

Patrick Dorr, Mike Westby, Susan Dobbs et al. · Antimicrobial Agents and Chemotherapy · 2005 · 1.1K citations · Full text

Standard Deviations, Immunology, Pharmacotherapy +19

Reduced Maximal Inhibition in Phenotypic Susceptibility Assays Indicates that Viral Strains Resistant to the CCR5 Antagonist Maraviroc Utilize Inhibitor-Bound Receptor for Entry

Mike Westby, Caroline Smith‐Burchnell, Julie Mori et al. · Journal of Virology · 2006 · 346 citations

Phenotypic Susceptibility Assays, Immunology, Ccr5 Antagonist +16

Novel Small-Molecule Inhibitors of RNA Polymerase III

Liping Wu, Jing Pan, Vala Thoroddsen et al. · Eukaryotic Cell · 2003 · 86 citations · Full text

Cyanide oxygenase and cyanase activities of<i>Pseudomonas fluorescens</i>NCIMB 11764

Patrick Dorr, Christopher J. Knowles · FEMS Microbiology Letters · 1989 · 52 citations · Full text

Oxygenase Activity, Ncimb 11764, Engineering +13

An Imidazopiperidine Series of CCR5 Antagonists for the Treatment of HIV: The Discovery of <i>N</i>-{(1<i>S</i>)-1-(3-Fluorophenyl)-3-[(3-<i>endo</i>)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798)

Paul A. Stupple, David V. Batchelor, Martin Corless et al. · Journal of Medicinal Chemistry · 2010 · 40 citations · Full text

Medicinal Chemistry, Maraviroc 1, Imidazopiperidine Series +15